- 米国企業
- PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc.PMCB
時価総額
$1694.2万
PER
| 2012年 4月30日 | 2013年 4月30日 | 2014年 4月30日 | 2015年 4月30日 | 2016年 4月30日 | 2017年 4月30日 | 2018年 4月30日 | 2019年 4月30日 | 2020年 4月30日 | 2021年 4月30日 | 2022年 4月30日 | 2023年 4月30日 | |
| Net loss | -1,899,312 | -1,598,102 | -27,254,020 | -10,854,509 | -6,063,784 | -4,443,685 | -6,828,841 | -4,067,228 | -3,826,888 | -3,551,236 | -4,239,161 | -4,315,993 |
| Other non-cash expenses | - | - | - | - | - | - | - | - | - | - | - | 171,744 |
| Stock issued for services | - | - | 18 | 1 | 491,684 | 107,500 | 309,881 | 316,539 | 473,141 | 70,326 | 34,846 | 2,278 |
| Stock issued for compensation | 2 | 984,696 | - | 735,189 | 405,080 | 420,480 | 580,360 | 293,329 | 368,650 | 194,261 | 33,146 | 7,334 |
| Stock-based compensation - options | - | - | - | 5 | 788,770 | 597,400 | 945,078 | 412,349 | 379,375 | 176,568 | 44,810 | 638,072 |
| Decrease in prepaid expenses and other current assets | - | - | - | - | - | - | - | - | - | - | 21,041 | 13,509 |
| Decrease in other assets | - | - | - | - | - | - | - | - | - | - | 316 | - |
| Increase (decrease) in accounts payable | 173,825 | 97,708 | -59,191 | 308,654 | -160,690 | 29,591 | -12,979 | -230,736 | 63,958 | -13,581 | 33,100 | -242,948 |
| Decrease in accrued expenses | 192,654 | 153,957 | 1,503 | -18,096 | 127,963 | 63,018 | 76,899 | 311,919 | 208,025 | -201,680 | -2,703 | -40,709 |
| Net cash used in operating activities | -259,289 | -390,426 | - | - | - | - | -5,079,395 | -2,877,912 | -2,338,373 | -3,330,889 | -4,117,319 | -3,793,731 |
| Net cash used in investing activities | -871,730 | -646,750 | - | - | - | - | - | - | - | - | - | - |
| Payment of insurance financing loan | - | - | - | - | - | - | - | - | - | - | 50,805 | - |
| Repurchase of common stock | - | - | - | - | - | - | - | - | - | - | - | 14 |
| Proceeds from exercise of warrants | - | - | - | - | - | - | - | - | - | - | - | 880 |
| Proceeds from sale of common stock, net of issuance costs | 21,000 | 1 | 9 | 4 | 4 | 5 | 3 | 2 | 3 | 5 | 87 | - |
| Net cash provided by (used) in financing activities | 1 | 1 | - | - | - | - | 3 | 2 | 3 | 5 | 87 | -13,559,743 |
| Effect of currency rate exchange on cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | - | -7,246 |
| Net increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | - | 1 | 83 | -17,360,720 |
| Cash paid during the years for income taxes | - | - | - | - | - | - | 800 | 800 | 800 | 800 | 1,600 | - |
| Cash paid during the years for interest expense | - | - | - | - | - | - | - | - | 453 | 2,267 | 509 | - |
| Non-cash equity issuance costs | - | - | - | - | - | - | - | - | - | - | 34 | - |